Document Type : Original Article
Department of Medicine Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Science, Qazvin, Iran
Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital of Tehran, Tehran, Iran
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
Department of Immunology, Tarbiat Modares University, Tehran, Iran
Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
Objective: Aberrant alterations in DNA methylation are known as one of the hallmarks of oncogenesis and play a vital
role in the progression of acute myeloid leukemia (AML). SMG1 is a member of the Phosphoinositide 3-kinases family,
acting as a tumor suppressor gene. The aim of this study was the evaluation of the expression level and methylation
status of SMG1 in AML.
Materials and Methods: In this follow-up study on AML patients admitted to Shariati Hospital, Tehran, Iran, the methylation status of SMG1 [performed by methylation-specific polymerase chain reaction (PCR)] and its expression
level (performed by qRT-PCR) were evaluated in three phases: newly diagnosed, under treatment and complete remission. The correlation of the methylation status of SMG1, its expression level, and clinical/paraclinical data was
analyzed by SPSS ver.25.
Results: This study on 18 patients and five control individuals showed that the CpG-islands of the SMG1 promoter
in newly diagnosed cases is hypomethylated compared to the normal group (P=0.002) The fold change of SMG1 expression levels in new cases is 0.464 ± 0.468, while the fold change of SMG1 expression levels in under-treatment and in-remission patients is 0.973 ± 1.159 and 0.685 ± 0.885, respectively. In under-treatment patients, white blood cell (WBC) count decreases 114176.36 cell/µl with each unit of increase in fold change of SMG1 (P<0.0001), and Hb unit increases 2.062 g/dl with each unit of increase in fold change (P<0.0001) Also, in the remission phase, the Hb unit increases 1.395 g/dl with each unit increase in fold change (P=0.019).
Conclusion: The robust results of our study suggest that the methylation and expression of have a high impact on the pathogenesis of AML. Also, the methylation and expression of SMG1 can play a prognostic role in AML.